Pear Bio is a computational biology company that has developed a functional precision medicine platform to optimize clinical cancer care and drug development. The platform uses microphysiological systems and 3D computer vision to measure cancer progression over time. Pear Bio cultures patient tumor samples and immune cells to test potential treatment options and combinations ex vivo. Pear Bio has tested ~200 patients to date, spanning 9 cancers, and has internal drug discovery programs against 5 novel druggable targets.